Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours

D. Foucré1, C. Bouchet1, K. Hacène2, N. Pourreau-Schneider3, A. Gentile1, P.M. Martin4, A. Desplaces1 & J. Oglobine1

1Laboratoire d’immunochimie, 2Unité de statistique, 3Laboratoire d’anatomo-pathologie, Centre René Huguenin, 35, rue Daily, 92211 Saint-Cloud; 4Laboratoire de Cancérologie Expérimentale, Faculté de Médecine Nord, Boulevard P. Dramard, 13266 Marseille, France.

Summary The concentrations of cathepsin D (Cath D), urokinase (uPA) and two plasminogen activator inhibitors (PAI-1 and PAI-2) were analysed in the cytosols of 130 human mammary tumours (43 benign tumours and 87 primary and unilateral breast carcinomas). uPA, PAI-1 and PAI-2 levels were measured by antigenic immunosays and Cath D by immunoradiometric assay. The median levels of the four parameters were significantly higher in the malignant tumours than in the benign ones. Cath D and uPA increased were 4-fold and 5-fold respectively. PAI-1 and PAI-2 increases were much more important, 74-fold and 29-fold respectively. In malignant tumours, median levels of Cath D and uPA did not vary according to classical prognostic factors (histologic grade, presence or absence of axillary lymph nodes, steroid receptors, UICC stage, tumour size, age, and menopausal status). However, PAI-1 decreased in ER+ and PR+ tumours and PAI-2 increased in menopausal women’s tumours. When Cath D, uPA, PAI-1 and PAI-2 levels in malignant tumours were compared, positive correlations were found for all combinations. The implication of plasminogen activator inhibitors in the phenomenon was surprising and merits further investigation using tools other than global antigen measurements in tumours.

Proteases play a role in metastatic dissemination. They contribute to basement membrane and connective tissue degradation, allowing vascular endothelial crossover (for review: Mullins & Rohrich, 1983; Tryggvason et al., 1987; Moscatelli & Rifkin, 1988; Gottesman, 1990). Diverse enzymes are produced in abundance by malignant cells and are implicated in tumour cell invasion: collagenases (for review: Liotta et al., 1982; Stetler-Stevenson, 1990); stromelysin (McDonnel & Matrisian, 1990); cathepsin B (Sloane et al., 1984; 1990); cathepsin D (Maguchi et al., 1988; Rochefort et al., 1990); heparanase (Nakajima et al., 1987); urokinase type plasminogen activator (for review: Dano et al., 1985; Markus, 1988; Testa & Quigley, 1990). Their proteolytic activities are often concentrated in the pericellular environment or cell surface bound (Zucker et al., 1985).

Among these enzymes, urokinase (uPA) has been extensively studied. uPA is a serine protease that transforms plasminogen into plasmin which is active on a large number of substrates. It can degrade basement membrane components (Liotta et al., 1981) and can activate type IV procollagenase (Paranipe et al., 1980; O’Grady et al., 1981). uPA can by itself degrade fibronectin (Gold et al., 1989). Inhibition of uPA using anti-urokinase antibodies has shown the importance of uPA in tumour invasion (Ossowski & Reich, 1983). The inhibition of uPA activity prevents laminin degradation (Boyd et al., 1989) and invasion of amniotic membrane (Mignatti et al., 1986; Yagel et al., 1989; Tsuboi & Rifkin, 1990) and of extracellular matrix (Massague et al., 1991). Moreover, transfection of uPA gene into H-ras-transformed fibroblasts, mouse L cells, and murine melanoma cells enhances invasion and metastasis of these cells (Axelrod et al., 1989; Cajot et al., 1989; Yu & Schultz, 1990). During the metastatic process, uPA is especially potent in mesenchymal infiltration and invasation by tumour cells (Ossowski, 1988a). uPA bound to membrane receptors is more active than free uPA in matrix degradation (Ossowski, 1988b; Hearing et al., 1988; Schlechte et al., 1989).

uPA activity is controlled by several specific inhibitors, PAI-1, PAI-2, PAI-3, protease nexin (for review: Hart & Rehemtulla, 1988). There are few studies on these inhibitors in malignant tissues, even though they have been detected in variable amounts in several cancer cell lines: bladder, lung, kidney, stomach (Naito et al., 1981); breast, uterus, lymphoma, epidermoid carcinoma (Cajot et al., 1986); neuroblastoma (Benjamin et al., 1989). Other cancer cell lines are completely devoid of plasminogen activator inhibitors (Quax et al., 1990). In two mammary carcinoma cell lines, Cajot et al. (1986) found PAI in T47D cells but not in MCF7 cells.

Cathepsin D (Cath D) is an aspartyl protease for which the normal function is protein degradation in lysosomes. In malignant cells, Cath D is also secreted (Maguchi et al., 1988; Capony et al., 1989; Rochefort et al., 1989). Cath D in conditioned media from certain cell lines can degrade extracellular matrix (Briozzo et al., 1988).

uPA and Cath D have been independently implicated in malignant progression, but until a recent report by Duffy et al. (1991), no studies have been made on detection of both proteases in the same tumours. In addition, since little is known of PAIs in tumours, we assayed in 43 benign and 87 malignant tumours, the concomitant production of uPA, Cath D, PAI-1 and PAI-2. In the malignant population, they were studied as a function of clinical, histological and biochemical factors.

Patients and methods

Patients

One hundred and thirty patients with primary and unilateral breast tumours were selected before treatment (43 benign tumours and 87 malignant tumours). For every patient, age, UICC stage, Scarf, Bloom and Richardson (1957) histological grade, number of involved lymph nodes, tumour size, menopausal status, oestrogen and progesterone receptor status were determined.

Tissue extraction

Tumours were snap frozen in liquid nitrogen after surgery (tumorectomy or mastectomy). Tissues were pulverised at...
4°C in 50 mM Tris pH 7.4, Triton X-100 (0.1%), Tween 80 (0.01%), 0.05 μM aprotinin buffer (10 ml g⁻¹ tumour). The homogenate was ultracentrifuged (105,000 g for 1 h). They cytosols were collected and stored at −80°C.

Assay of Cath D

Cath D was determined in breast tumour cytosols using an immunoradiometric assay (ELISA-Cath D, CIS Biotechs, Gif-sur-Yvette, France). The first monoclonal antibody was coated in the solid phase and the second monoclonal antibody, raised against two different sites of Cath D heavy chain, was radiolabelled with 125 iodine. This assay measured pro-cathepsin D (52 kD), mature Cath D (48 kD) and Cath D heavy chain (34 kD). Cytosols were diluted 1/100 and incubated with the two monoclonal antibodies at 37°C with agitation for 2 h. After three washes, the radioactivity was measured with a gamma scintillation counter. Results were obtained from a standard curve under the same conditions. Assays were performed in duplicate.

Assay of uPA, PAI-1 and PAI-2

Antigens were measured by commercially available ELISA kits (TINT ELISE Biopool, Umeå, Sweden). Microtiter plates were coated with monoclonal antibodies raised against:

- For uPA assay: pro-urokinase, 33 kD uPA, 50 kD uPA, and uPA bound to PAI.
- For PAI-1 assay: active and latent PAI-1, and PAI-1 bound to uPA and tPA.
- For PAI-2 assay: non-glycosylated (47 kD) and glyco-sylated (60 kD) forms.

Cytosols, diluted 1/2 for uPA and PAI-2 antigens and 1/6 for PAI-1, were incubated for 3 h at room temperature with agitation. Then, the second polyclonal antibody labelled with peroxidase was added for 1 h with agitation. After three washes, antigens were revealed with ortho-phenylenediamine. The reaction was stopped with sulphuric acid. Results were obtained from standard curves under the same conditions. Assays were performed in triplicate.

Oestrogen and progesterone receptor assays

Steroid receptors were measured by the dextran-coated charcoal method recommended by EORTC (1980). A cut-off level of 10 fmol mg⁻¹ protein was used to determine positive or negative receptor status.

Protein determination

Protein levels were assayed using the Bradford method (Bradford, 1976, Bio-Rad, California, USA).

Statistical analysis

The analysis of differences was performed using Student’s t-test. Correlations were calculated by Spearman’s method (correlation coefficient rs) and Pearson’s method (correlation coefficient rp). All tests were performed at a significance level of P = 0.05.

### Results

Cath D, uPA, PAI-1, and PAI-2 concentrations in benign and malignant breast tumours (Table 1)

Cath D (Figure 1) and uPA (Figure 2). All of the benign and malignant tumours contained Cath D. uPA was present in all malignant tumours and in 86% of benign tumours. The mean levels of Cath D and uPA were significantly higher in malignant tumours than in benign tumours (P < 0.00001). The increase was approximately the same for the two proteases: about 4-fold for Cath D and 5-fold for uPA.

PAI-1 (Figure 3) and PAI-2 (Figure 4) 71% of benign tumours had neither PAI-1 nor PAI-2. Twenty-seven per cent of benign tumours contained only PAI-1 or PAI-2. PAI-1 was present in 10% of benign tumours and PAI-2 in 22%. A single benign tumour produced both inhibitors.

Seven per cent of malignant tumours had neither PAI-1 nor PAI-2. PAI-1 was present in 80% of malignant tumours and PAI-2 in 70%. Fifty-seven per cent contained both inhibitors. Thirty-seven per cent contained only one of the two inhibitors.

Mean concentrations of PAI-1 and PAI-2 were significant-

### Table 1 Mean concentrations of Cath D, uPA, PAI-1 and PAI-2 in benign and malignant breast tumours

| Tumours          | Cath Dᵃ | Standard deviation | uPAᵇ | Standard deviation | PAI-1ᵇ | Standard deviation | PAI-2ᵇ | Standard deviation |
|------------------|---------|--------------------|------|--------------------|--------|--------------------|--------|--------------------|
| Benign n = 43    | 16.58   | 1.75               | 0.29 | 0.08               | 0.26   | 0.02               | 0.06   | 0.17               | 0.42   |
| Malignant n = 87 | 70.68   | 42.26              | 1.52 | 1.23               | 1.48   | 2.33               | 5      | 11.73              |

ᵃMean concentration pmol mg⁻¹ protein.ᵇMean concentration ng mg⁻¹ protein.

Figure 1: Cath D content in cytosols of mammary tumours. Horizontal bars indicate median values.
ly higher in malignant than in benign tumours (respectively \( P = 0.00015 \) and \( P = 0.0087 \)). These increases were elevated: about 74-fold for PAI-1 and 29-fold for PAI-2.

**Relation between Cath D, uPA, PAI-1, PAI-2 and histological, clinical and biochemical parameters in malignant tumours (Table II)**

**Cath D and uPA** The mean concentration of Cath D and uPA were independent of patient's age and menopausal status, tumour stage, grading and size, lymph node involvement, oestrogen and progesterone receptor status.

**PAI-1 and PAI-2** PAI-1 varied only with steroid receptor status, and was independent of other classical prognostic factors. The mean concentration of PAI-1 was significantly lower when the tumours lacked oestrogen \((P = 0.001)\) and progesterone \((P = 0.016)\) receptors.

PAI-2 varied only according to patient's hormonal status. Menopausal women's tumours contained 4-fold more PAI-2 than non-menopausal women's tumours \((P = 0.036)\).

**Correlation between Cath D, uPA, PAI-1, PAI-2 in benign and malignant tumours**

In benign tumours, Cath D and uPA concentrations were significantly and linearly correlated \((rs = 0.583, P = 0.0001; \; rp = 0.486, P = 0.0016)\). Due to the absence of PAI-1 and PAI-2 in the majority of benign tumours, no correlation could be found.

In malignant tumours, Cath D and uPA concentrations were significantly, but nonlinearly correlated (Table III). They were also significantly correlated with concentrations of PAI-1 and PAI-2. Cath D was strongly linearly correlated with PAI-1 and nonlinearly correlated with PAI-2. uPA was nonlinearly correlated with PAI-1 and PAI-2. There was a clear linear correlation between PAI-1 and PAI-2.

---

### Table II Levels of Cath D, uPA, PAI-1 and PAI-2 compared with histological, clinical, and biochemical factors in malignant tumours

| Factors | Number of patients | Cath D | Standard deviation | uPA | Standard deviation | PAI-1 | Standard deviation | PAI-2 | Standard deviation |
|---------|-------------------|--------|--------------------|-----|--------------------|-------|--------------------|-------|--------------------|
| Age (n = 87) | < 50 years | 29 | 66.46 | 36.85 | 1.32 | 0.80 | 1.69 | 2.85 | 1.55 | 2.79 |
| 50–65 years | 26 | 68.41 | 43.05 | 1.92 | 1.93 | 1.29 | 1.66 | 4.20 | 9.86 |
| > 65 years | 32 | 76.41 | 46.70 | 1.37 | 0.66 | 1.43 | 2.35 | 8.63 | 16.32 |
| UICC stage (n = 87) | I | 17 | 54.62 | 30.17 | 1.24 | 0.85 | 0.54 | 0.68 | 1.46 | 2.57 |
| II | 62 | 75.23 | 43.54 | 1.58 | 1.37 | 1.73 | 2.66 | 6.38 | 13.67 |
| III | 8 | 70.72 | 50.76 | 1.64 | 0.65 | 1.51 | 1.25 | 2.10 | 2.44 |
| Scarff, Bloom & Richardson grading (n = 82) | I | 14 | 52.97 | 36.61 | 1.41 | 0.98 | 0.67 | 0.86 | 4.21 | 5.05 |
| II | 42 | 72.3 | 39.14 | 1.47 | 0.91 | 1.48 | 2.88 | 6.04 | 14.86 |
| III | 26 | 84.88 | 46.45 | 1.83 | 1.75 | 2.16 | 1.89 | 4.59 | 9.69 |
| Number of lymph nodes involved (n = 85) | 0 | 38 | 68.6 | 40.91 | 1.35 | 0.90 | 1.58 | 3.17 | 6.96 | 15.63 |
| 1–3 | 26 | 65.45 | 38.10 | 1.88 | 1.86 | 1.23 | 1.07 | 3.48 | 6.13 |
| > 3 | 21 | 87.49 | 47.04 | 1.48 | 0.59 | 1.72 | 1.77 | 3.82 | 8.94 |
| Tumour size (n = 87) | < 20 mm | 22 | 55.06 | 34.75 | 1.67 | 1.00 | 1.02 | 1.51 | 4.17 | 6.38 |
| 20–37 mm | 51 | 73.76 | 40.20 | 1.51 | 1.43 | 1.60 | 2.78 | 6.25 | 14.72 |
| > 37 mm | 14 | 83.13 | 54.75 | 1.31 | 0.71 | 1.73 | 1.51 | 1.91 | 2.68 |
| Menopausal status (n = 87) | premenopausal | 36 | 68.54 | 37.00 | 1.33 | 0.77 | 1.63 | 2.64 | 1.85 | 3.18 |
| postmenopausal | 51 | 72.19 | 45.91 | 1.65 | 1.46 | 1.37 | 2.12 | 7.20 | 14.73 |
| Oestrogen receptors (n = 84) | ER + | 60 | 69.44 | 42.68 | 1.37 | 0.87 | 0.96 | 1.14 | 4.10 | 7.39 |
| ER – | 24 | 77.67 | 41.26 | 1.90 | 1.85 | 2.79 | 3.80 | 7.94 | 19.60 |
| Progesterone receptors (n = 84) | PR + | 62 | 69.63 | 43.52 | 1.39 | 0.90 | 1.12 | 1.37 | 4.24 | 8.06 |
| PR – | 22 | 78.31 | 38.11 | 1.90 | 1.89 | 2.52 | 3.91 | 7.71 | 19.28 |

*Mean level pmol mg\(^{-1}\) protein; \(^{b}\)Mean level ng mg\(^{-1}\) protein; \(^{c}\)Significant difference \(P = 0.001\); \(^{d}\)Significant difference \(P = 0.016\); \(^{e}\)Significant difference \(P = 0.036\).*
**Discussion**

One originality in this study was the concomitant measurement of uPA, Cath D, PAI-1 and PAI-2 in a series of benign and malignant tumours. The major findings were the significant increases of the two proteases and particularly of two anti-proteases in malignant compared to benign breast tumours and the positive correlation for all combinations.

Our results are in agreement with those of others concerning the two enzymes. Individually uPA and Cath D levels have been found to be elevated in malignant tumours compared to benign counterparts. Urokinase concentration increase (activity, antigen, mRNA) in malignant breast tumours was observed by many authors (Evers et al., 1982; O'Grady et al., 1985; Layer et al., 1987; Sappino et al., 1987; Jänicke et al., 1990). Cath D concentration was also higher in malignant breast tumours compared to benign ones (Abecassis et al., 1984; Duffy et al., 1991) and to normal mammary tissue (Capony et al., 1989; Tandon et al., 1990; Duffy et al., 1991). In addition, Duffy et al. (1991) recently found a simultaneous rise of uPA and Cath D concentrations in a series of malignant breast tumours. This positive correlation that we also found in malignant tumours suggests the possible intervention of uPA and Cath D in tumour invasion. Mignatti et al. (1986) and Reich et al. (1988) have previously shown the existence of a proteolytic cascade (plasminogen activators, plasmin, type IV collagenase) for basal membrane degradation in vitro.

High levels of cytosolic uPA (Duffy et al., 1990; Jänicke et al., 1990) and Cath D (Spyratos et al., 1989; Tandon et al., 1989; Thorpe et al., 1989; Romain et al., 1990; Duffy et al., 1991) in breast cancers have been associated with shorter disease-free and overall survival. We, therefore, looked for relationships between proteases and anti-proteases as a function of classical prognostic factors. Like others, we found no significant variation of uPA (O'Grady et al., 1985; Duffy et al., 1986; Sappino et al., 1987; Needham et al., 1988; Duffy et al., 1990; Jänicke et al., 1990; Mira-y-Lopez et al., 1991) or Cath D (Abecassis et al., 1984; Maudelonde et al., 1988; Brouillet et al., 1990; Romain et al., 1990) concentrations with tumour grade, lymph node invasion, tumour size or steroid hormone receptors. In contrast, we found that PAI-1 concentration decreased in tumours with oestrogen or progesterone receptors, whereas PAI-2 increased significantly in malignant tumours of post-menopausal patients compared with non-menopausal patients. Hormonal regulation of PAIs has already been reported (for review: Adreasen et al., 1990). However, Cohen et al. (1989) have found that PAI-1 and PAI-2 are independently regulated. The hormonal regulation of PAIs could possibly explain the correlation that we found between Cath D and PAI increase in malignant tumours, because Rochefort et al. (1989) have demonstrated the induction of Cath D by oestrogen.

Jänicke et al. (1990) have also reported a significant increase of PAI-1 concentration in malignant breast tumours. However, their results differ from ours in that they found no correlation between urokinase and PAI-1 concentrations. In addition, the increase that they found for PAI-1 was small (about 10-fold) compared to the 74-fold increase that we found in malignant over benign tumours. This discrepancy may be due to different buffers and anti-urokinase antibodies used.

The very high PAI-1 and PAI-2 increases that occurred with malignancy may counteract urokinase-mediated tissue degradation by tumour cells. In vitro studies have shown that PAI-1 and PAI-2 can inhibit plasminogen-dependent cellular matrix degradation by colon carcinoma cells (Cajot et al., 1990; Baker et al., 1990). However, the function of these inhibitors in malignancy is puzzling. Maybe they have an activity other than that of inhibiting PAs. GdNPF (gli-derived neurite promoting factor) which inhibits PAs, also regulates the migration of neuronal cells (Gloor et al., 1986). Other small molecular weight serine protease inhibitors, secreted by human hepatoma cells, stimulated endothelial cell growth (McKeehan et al., 1986). If such functions should
exist for PAI, they could promote tumour cell invasiveness.

Since our technique measured global enzyme and inhibitor levels in cytosols of pulsedverised tumours, we can ask the question about the tissue compartment responsible for their production. uPA, Cath D and PAIs have been found in plasma (Saito et al., 1990; Freis et al., 1988; Kruithof et al., 1987), and in many types of normal cells (Bennik et al., 1981; Jaffe, 1987; Chapman et al., 1982; Bergman et al., 1986; Keski-Oja et al., 1988; Wilson et al., 1987; Tissot et al., 1984; Wohlswend et al., 1987). However, we can consider that the tumour cells are the major producer. Saito et al. (1990) have shown that the plasmatic concentration of uPA did not vary between patients with ovarian or uterine benign and malignant tumours. By immunohistochemistry, Jânickie et al. (1990) and Costantini et al. (1991) have found uPA in the cytoplasm and the plasma membrane of breast tumour cells. For Cath D an immunohistochemistry study of benign and malignant breast tumours has shown that procathepsin D staining was more intense in malignant than in benignmastopathies ( Garcia et al., 1987). The distribution of Cath D in human breast appears to be relatively specific for mamm-

mary epithelial cells and to be associated with tumour development ( Garcia et al., 1984; Garcia et al., 1986).

Besides, in culture, uPA, Cath D, and PAI-1 are produced by many breast carcinoma cell lines (Tissot et al., 1984; Cajot et al., 1986; Quax et al., 1990; Brozoo et al., 1988). Moreover, Costantini et al. (1991) have observed PAI-1 in breast tumour cells using immunohistochemical technique. To our knowledge PAI-2 has not been reported in breast carcinoma cell but it is produced by other carcinoma cell lines (Schleef et al., 1988; Heidmann et al., 1989; George et al., 1990).

Further studies on the coextensive production of proteases and anti-proteases in malignant tumours should shed a light on their role in matrix degradation.

Thanks are due to Dr M. Pagano for his critical reading of the manuscript and to Mrs F. Spyraatos for her assistance. We also thank Pr J. Rousset, Director of Centre R. Hugguin and Dr J. Gest, President of the Association pour la Recherche contre le Cancer de Saint-Cloud for their support. This work was supported by the Ligue Nationale de Lutte contre le Cancer (Comité des Hauts de Seine).

References

ABECASSIS, J., COLLARD, R., EBER, M., PUSEL, J., FRICKER, J.P. & METHLIN, G. (1984). Proteinases and sialytransferase in human breast tumours. Int. J. Cancer, 33, 821.

ANDREASEN, P.A., GEORG, B., LUND, L.R., RICCIO, A. & STACEY, S.N. (1990). Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell Endocrinol., 68, 1.

AXELROD, J.J., REICH, R. & MISKIN, R. (1989). Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH3T3 cells. Mol. Cell Biol., 9, 2133.

BAKER, M.S., BLEAKLEY, P., WOODROW, G.C. & DOE, W.F. (1990). Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res., 50, 4676.

BENJAMIN, L.A., MCGARRY, R.C. & HART, D.A. (1989). Effect of retinoic acid on human neuroblastoma: correlation between morphological differentiation and changes in plasminogen activator and inhibitor activity. Cancer Chemother. Pharmacol., 25, 25.

BERGMAN, B.L., SCOTT, R.W., BAIPAUL, A., WATTS, S. & BAKER, J.B. (1986). Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibition, pro tease nexin 1. Proc. Natl Acad. Sci. USA, 83, 996.

BERNIK, M.B., WINGAARDTS, G. & RIJKEN, D.C. (1981). Production by human tissues in cultures of immunologically distinct, multiple molecular weight forms of plasminogen activators. Ann. NY Acad. Sci., 378, 592.

BLOOM, H.J.G. & RICHARDSON, W.W. (1957). Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer, 11, 35.

BOYD, D., ZIOBER, B., CHAKRABARTY, M. & BRATTAIN, M. (1989). Examination of urokinase protein/transfer levels and their relationship with laminin degradation in cultured colon carcinoma. Cancer Res., 49, 816.

BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Annal Biochem., 72, 248.

BROZZO, P., MORISSET, M., CAPONY, F., ROUGEOY, C. & ROCHEFORT, H. (1988). In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res., 48, 3688.

Table III Correlations between concentrations of Cath D, uPA, PAI-1 and PAI-2 in malignant tumours

| Factors       | uPA        | PAI-1       | PAI-2       |
|---------------|------------|-------------|-------------|
| rs            | 0.298 P < 0.003 | 0.473 P < 0.0001 | 0.256 P = 0.011 |
| Cath D        | rp = 0.145 P = 0.15 | rp = 0.245 P = 0.015 | rp = 0.119 P = 0.25 |
| rs            | 0.282 P = 0.004 | 0.270 P = 0.007 | 0.048 P < 0.0001 |
| uPA           | rp = 0.158 P = 0.11 | rp = 0.03 P = 0.77 | 0.233 P = 0.026 |
| PAI-1         | rs = 0.469 P < 0.0001 |          |            |

rs: Spearman correlation coefficient; rp: Pearson correlation coefficient. P = 0.05 non significant.
ZUCKER, P. (1984). The lymphoid cell in the immune response. Annu. Rev. Immunol., 2, 273.

ZUMやす, S., YAMASHITA, Y., NAKAO, M., MIYAMOTO, S., and YANAGISAWA, S. (1983). Characterization of angiogenesis factor from human cerebral angiomas. J. Neurosurg., 59, 719.

ZWILLING-KOEPPEL, P. and KOPP, E. (1980). The role of the lymphokine-activated killer cell in the immune response. Immunol. Today, 1, 205.

ZUSSMAN, S. (1980). The role of the lymphokine-activated killer cell in the immune response. Immunol. Today, 1, 205.

ZUSSMAN, S. (1980). The role of the lymphokine-activated killer cell in the immune response. Immunol. Today, 1, 205.

ZUSSMAN, S. (1980). The role of the lymphokine-activated killer cell in the immune response. Immunol. Today, 1, 205.
THORPE, K., NAGASHIMA, M., IWATA, M. & 4 others (1990). The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. *Thromb. Res.*, 58, 355.

SAPPINO, A.P., BUSSO, N., BELIN, D. & VASSALI, J.D. (1987). Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. *Cancer Res.*, 47, 4043.

SCHLECHTE, W., MURANO, G. & BOYD, D. (1989). Examination of the role of the urokinase receptor in human colon mediated laminin degradation. *Cancer Res.*, 49, 6064.

SCHLEEF, R.R., WAGNER, N.V. & LOSKUTOFF, D.J. (1988). Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells. *J. Cell. Physiol.*, 134, 269.

SLOANE, B.F., SADLER, J.G., EVENS, C. & 4 others (1984). Cathepsin B-like cysteine proteinases and tumor metastasis. *Cancer Bull.*, 36, 196.

SLOANE, B.F., MOIN, K., KREPELA, E. & ROZHN, J. (1990). Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. *Cancer Metastasis Rev.*, 9, 333.

SPYRATOS, F., BROUILLET, J.P., DEFRENNE, A. & 7 others (1989). Cathepsin D: an independent prognostic factor for metastasis of breast cancer. *Lancet*, ii, 1115.

STETLER-STEVenson, W.G. (1990). Type IV collagenases in tumor invasion and metastasis. *Cancer Metastasis Rev.*, 9, 289.

TANDON, A.K., CLARK, G.M., CHAMNESS, G.C., CHIRGWIN, J.M. & MCGUIRE, W.L. (1990). Cathepsin D and prognosis in breast cancer. *N. Engl. J. Med.*, 322, 297.

TESTA, J.E. & QUIGLEY, J.P. (1990). The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. *Cancer Metastasis Rev.*, 9, 353.

THORPE, S.M., ROCHEFORT, H., GARCIA, M. & 7 others (1989). Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. *Cancer Res.*, 49, 6008.

TISsot, J.D., HAuert, J. & BACHMANN, F. (1984). Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. *Int. J. Cancer*, 34, 295.

TRYGGVASON, K., HÖYHTYÄ, M. & SALO, T. (1987). Proteolytic degradation of extracellular matrix in tumor invasion. *Biochim. Biophys. Acta*, 907, 191.

TSUBOI, R. & RIFKIN, D.B. (1990). Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity. *Int. J. Cancer*, 46, 56.

WILSON, E.L. & FRANCIS, G.E. (1987). Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human hemopoietic cells. *J. Exp. Med.*, 165, 1609.

WOHLWEND, A., BELIN, D. & VASSALI, J.D. (1987). Plasminogen activator-specific inhibitors in mouse macrophages: in vivo and in vitro modulation of their synthesis and secretion. *J. Immunol.*, 139, 1278.

YAGEL, S., KHOKHA, R., DENHART, D.T., KERBEL, R.S., PARHAR, R.S. & LALA, P.K. (1989). Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo. *J. Natl Cancer Inst.*, 81, 768.

Yu, H. & SCHULTZ, R.M. (1990). Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. *Cancer Res.*, 50, 7623.

ZUCKER, S., LYSIK, R.M., RAMAMURTHY, N.S., GOLUB, L.M., WIE-MAN, J.M. & WILKIE, D.P. (1985). Diversity of melanoma plasma membrane proteins: inhibition of collagenolytic and cytolytic activities by minocycline. *J. Natl Cancer Inst.*, 75, 517.